TELIX PHARMACEUTICALS LIMITED - Announcements

3.08%

$17.64

Market Cap $5.969B

Healthcare Biotechnology

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on... Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

TLX	AGM Results of Meeting		12/05/21	254.91KB	Share
TLX	CEOs Address to AGM		12/05/21	946.7KB	Share
TLX	Chairmans Address to AGM		12/05/21	223.67KB	Share
TLX	Phase III Prostate Cancer Therapy Clinical Trial Commences	PRICE SENSITIVE	10/05/21	217.94KB	Share
TLX	Executive Leadership Appointments and Establishment of APAC		03/05/21	204.42KB	Share
TLX	Telix Appoints Mr Richard Valeix as EMEA President		03/05/21	203.62KB	Share
TLX	Manufacturing Agreement with Global Medical Solutions		27/04/21	207.38KB	Share
TLX	Activities Report and App 4C for quarter ended 31 March 2021	PRICE SENSITIVE	22/04/21	1.28MB	Share
TLX	Japanese Renal Cancer Imaging Trial Meets Study Objectives	PRICE SENSITIVE	21/04/21	210.56KB	Share
TLX	Launch of International NOBLE Registry for SPECT Imaging	PRICE SENSITIVE	19/04/21	213.59KB	Share
TLX	TGA commences priority evaluation process for Illuccix	PRICE SENSITIVE	14/04/21	212.57KB	Share
TLX	AGM Notice of Meeting and Explanatory Memorandum		12/04/21	404.67KB	Share
TLX	Agreement with GRAM for commercial manufacture of Illucix		31/03/21	204.97KB	Share
TLX	Cleansing Notice - shares issued upon exercise of options		26/03/21	73.57KB	Share
TLX	App 2A - quotation of shares issued upon exercise of options		26/03/21	224.53KB	Share
TLX	Global Agreements with ITM for Lutetium-177 Supply		18/03/21	212.1KB	Share
TLX	S&P DJI Announces March 2021 Quarterly Rebalance	PRICE SENSITIVE	12/03/21	183.24KB	Share
TLX	Cleansing Notice - issue of shares upon exercise of options		09/03/21	73.72KB	Share
TLX	App 2A - quotation of shares on exercise of options		09/03/21	223.46KB	Share
TLX	Cleansing Notice - issue of shares upon exercise of options		02/03/21	73.54KB	Share
TLX	App 2A - quotation of shares on exercise of options		02/03/21	223.64KB	Share
TLX	2020 Annual Report		26/02/21	3.8MB	Share
TLX	Appendix 4E - Results for announcement to the market	PRICE SENSITIVE	26/02/21	155KB	Share
TLX	Corporate Governance Statement year ended 31 December 2020		26/02/21	482.95KB	Share
TLX	Appendix 4G - key to governance disclosures		26/02/21	234.34KB	Share
TLX	Shareholder update - year ended 31 December 2020	PRICE SENSITIVE	26/02/21	2.66MB	Share
TLX	PMDA clearance to commence Prostate Cancer Imaging Study		22/02/21	208.62KB	Share
TLX	Czech Republic Grants National Authorisation for TLX591 Kit	PRICE SENSITIVE	16/02/21	211.79KB	Share
TLX	Notification of Conference Call for FY2020 Results		16/02/21	192.08KB	Share
TLX	Collaboration with Heidelberg University Hospital		10/02/21	202.43KB	Share
TLX	Telix Pursues Direct Benelux Product Distribution		08/02/21	214.02KB	Share
TLX	Appendix 3G - issue of unlisted share options		29/01/21	232.02KB	Share
TLX	Appendix 4C and Activities Report for December 2020 Quarter	PRICE SENSITIVE	29/01/21	1.34MB	Share
TLX	First US patients dosed in Ph III ZIRCON trial		25/01/21	226.92KB	Share
TLX	TLX101 Glioblastoma Therapy - Clinical Update		23/12/20	213.92KB	Share
TLX	Cleansing Notice under section 708A Corporations Act		17/12/20	74.55KB	Share
TLX	Appendix 2A - issue of shares from exercise of options		17/12/20	226.81KB	Share
TLX	Change in substantial holding		17/12/20	685.08KB	Share
TLX	New Drug Submission filed with Health Canada for TLX591-CDx	PRICE SENSITIVE	16/12/20	218.89KB	Share
TLX	Urologic Oncology Alliance with Mauna Kea Technologies		16/12/20	203.05KB	Share
TLX	IP Agreement with U Southampton for access to TRALA data	PRICE SENSITIVE	14/12/20	219.58KB	Share
TLX	Cleansing Notice under section 708A Corporations Act		14/12/20	74.66KB	Share
TLX	Appendix 2A - issue of shares from exercise of options		14/12/20	225.52KB	Share
TLX	Appendix 2A - shares issued as consideration for acquisition		14/12/20	236.33KB	Share
TLX	Telix Completes Acquisition of TheraPharm GmbH	PRICE SENSITIVE	14/12/20	208.43KB	Share
TLX	Telix and Kanazawa University Phase I trial of TLX591-CDx		14/12/20	211.07KB	Share
TLX	Release of shares from voluntary escrow		10/12/20	190.32KB	Share
TLX	FDA New Drug Application for TLX591-CDx Proceeds to Review	PRICE SENSITIVE	09/12/20	222.21KB	Share
TLX	TGA Priority Review Granted for Prostate Cancer Imaging	PRICE SENSITIVE	07/12/20	211.48KB	Share
TLX	Overview of ProstACT Phase III Study - Investor supplement		03/12/20	8.92MB	Share
TLX	ProstACT Phase III Study Clinical Development Update	PRICE SENSITIVE	03/12/20	214.29KB	Share
TLX	Telix and DuChemBio - South Korea Partnership	PRICE SENSITIVE	03/12/20	223.7KB	Share
TLX	Investor Briefing on First-in-Human Translation of TLX592		02/12/20	2.12MB	Share
TLX	Approval for Ph I study of next generation product TLX592		02/12/20	210.83KB	Share
TLX	FDA Approves 68Ga-PSMA Imaging for Use at UCLA and UCSF		02/12/20	211.09KB	Share
TLX	Briefing for Investor call - TheraPharm GmbH Acquisition	PRICE SENSITIVE	01/12/20	1.98MB	Share
TLX	Acquisition of TheraPharm GmbH - Investor Call	PRICE SENSITIVE	30/11/20	190.7KB	Share
TLX	Proposed issue of Securities - TLX		30/11/20	25.02KB	Share
TLX	Telix Acquires TheraPharm GmbH	PRICE SENSITIVE	30/11/20	252.49KB	Share
TLX	Trading Halt	PRICE SENSITIVE	27/11/20	278.66KB	Share
TLX	Prostate Cancer Therapy FDA Meeting Update	PRICE SENSITIVE	25/11/20	205.99KB	Share
TLX	NDA for Prostate Cancer Imaging accepted by US FDA	PRICE SENSITIVE	24/11/20	220.55KB	Share
TLX	TLX receives EUR545k Belgian Research Grant		19/11/20	211.91KB	Share
TLX	Becoming a substantial holder		09/11/20	5.97MB	Share
TLX	App 2A quotation for shares issued in strategic transaction		06/11/20	234.14KB	Share
TLX	Appendix 3Y - change in Director interests - O Buck		03/11/20	216.93KB	Share
TLX	Cleansing Notice - issue of shares from exercise of options		03/11/20	74.75KB	Share
TLX	Appendix 2A - issue of shares on exercise of options		03/11/20	225.14KB	Share
TLX	Investor Briefing - Asia Strategy	PRICE SENSITIVE	03/11/20	2.42MB	Share
TLX	Investor Call - Strategic Licence and Commercial Partnership		02/11/20	191.84KB	Share
TLX	Appendix 3B - Proposed Issue of Securities		02/11/20	664.79KB	Share
TLX	Strategic Licence and Partnership for Greater China Market	PRICE SENSITIVE	02/11/20	244.19KB	Share
TLX	Trading Halt	PRICE SENSITIVE	30/10/20	278.57KB	Share
TLX	App 4C and Activities Report for September 2020 Quarter	PRICE SENSITIVE	30/10/20	1.31MB	Share
TLX	Licence Agmt with DKFZ for Image-Guided Prostate Surgery		28/10/20	220.09KB	Share
TLX	Completion of PhI Enrolment of Japanese Renal Cancer Study		27/10/20	206.79KB	Share
TLX	Appendix 3G - issue of Rights under Equity Incentive Plan		13/10/20	234.11KB	Share
TLX	FDA grants Orphan Drug Designation for glioma imaging agent	PRICE SENSITIVE	06/10/20	216.44KB	Share
TLX	Telix submits NDA to US FDA for Prostate Cancer Imaging	PRICE SENSITIVE	24/09/20	206.06KB	Share
TLX	First patients dosed in Phase I study of APOMAB theranostic		21/09/20	205.38KB	Share
TLX	Strategic Collaboration with Varian for Prostate Imaging	PRICE SENSITIVE	03/09/20	217.32KB	Share
TLX	IRE Distribution Partnership for Prostate Cancer Imaging	PRICE SENSITIVE	01/09/20	206.15KB	Share
TLX	FDA grants orphan drug designation for TLX102	PRICE SENSITIVE	31/08/20	203.85KB	Share
TLX	Half Year Shareholder Update		21/08/20	3.09MB	Share
TLX	Report for half-year to 30 June 2020	PRICE SENSITIVE	20/08/20	951.8KB	Share
TLX	First patient dosed in renal cancer imaging study in Japan		18/08/20	210.46KB	Share
TLX	Drug Master File for Glioblastoma Product Filed with FDA		11/08/20	209.75KB	Share
TLX	Investor call - H1 Results and Company Update		11/08/20	198.31KB	Share
TLX	Appendix 4C and Activities Report - June 2020 quarter	PRICE SENSITIVE	27/07/20	1.25MB	Share
TLX	Receipt of $11.4M R&D tax rebate	PRICE SENSITIVE	21/07/20	204.14KB	Share
TLX	App 2A - issue of shares following exercise of options		15/07/20	167.63KB	Share
TLX	Strategic collaboration with RefleXion for high-risk cancers		08/07/20	187.55KB	Share
TLX	FDA feedback on Prostate Cancer Therapy Phase 3 Trial Design		08/07/20	188.15KB	Share
TLX	App 3G - issue and lapse of unlisted share options		02/07/20	353.15KB	Share
TLX	FDA grants breakthrough designation for TLX250-CDx product	PRICE SENSITIVE	01/07/20	197.32KB	Share
TLX	Recommencement of ZIRCON Phase III Trial Recruitment in EU		18/06/20	180.7KB	Share
TLX	S&P DJI Announces June 2020 Quarterly Rebalance	PRICE SENSITIVE	12/06/20	223.16KB	Share
TLX	Update on New Drug Application for Prostate Cancer Imaging		10/06/20	179.58KB	Share
TLX	Presentation to Jefferies Virtual Healthcare Conference		04/06/20	13.7MB	Share
TLX	Appointment of Dr Colin Hayward as Chief Medical Officer		02/06/20	188.6KB	Share

TLX AGM Results of Meeting
12/05/21		254.91KB	Share
TLX CEOs Address to AGM
12/05/21		946.7KB	Share
TLX Chairmans Address to AGM
12/05/21		223.67KB	Share
TLX Phase III Prostate Cancer Therapy Clinical Trial Commences
10/05/21	PRICE SENSITIVE	217.94KB	Share
TLX Executive Leadership Appointments and Establishment of APAC
03/05/21		204.42KB	Share
TLX Telix Appoints Mr Richard Valeix as EMEA President
03/05/21		203.62KB	Share
TLX Manufacturing Agreement with Global Medical Solutions
27/04/21		207.38KB	Share
TLX Activities Report and App 4C for quarter ended 31 March 2021
22/04/21	PRICE SENSITIVE	1.28MB	Share
TLX Japanese Renal Cancer Imaging Trial Meets Study Objectives
21/04/21	PRICE SENSITIVE	210.56KB	Share
TLX Launch of International NOBLE Registry for SPECT Imaging
19/04/21	PRICE SENSITIVE	213.59KB	Share
TLX TGA commences priority evaluation process for Illuccix
14/04/21	PRICE SENSITIVE	212.57KB	Share
TLX AGM Notice of Meeting and Explanatory Memorandum
12/04/21		404.67KB	Share
TLX Agreement with GRAM for commercial manufacture of Illucix
31/03/21		204.97KB	Share
TLX Cleansing Notice - shares issued upon exercise of options
26/03/21		73.57KB	Share
TLX App 2A - quotation of shares issued upon exercise of options
26/03/21		224.53KB	Share
TLX Global Agreements with ITM for Lutetium-177 Supply
18/03/21		212.1KB	Share
TLX S&P DJI Announces March 2021 Quarterly Rebalance
12/03/21	PRICE SENSITIVE	183.24KB	Share
TLX Cleansing Notice - issue of shares upon exercise of options
09/03/21		73.72KB	Share
TLX App 2A - quotation of shares on exercise of options
09/03/21		223.46KB	Share
TLX Cleansing Notice - issue of shares upon exercise of options
02/03/21		73.54KB	Share
TLX App 2A - quotation of shares on exercise of options
02/03/21		223.64KB	Share
TLX 2020 Annual Report
26/02/21		3.8MB	Share
TLX Appendix 4E - Results for announcement to the market
26/02/21	PRICE SENSITIVE	155KB	Share
TLX Corporate Governance Statement year ended 31 December 2020
26/02/21		482.95KB	Share
TLX Appendix 4G - key to governance disclosures
26/02/21		234.34KB	Share
TLX Shareholder update - year ended 31 December 2020
26/02/21	PRICE SENSITIVE	2.66MB	Share
TLX PMDA clearance to commence Prostate Cancer Imaging Study
22/02/21		208.62KB	Share
TLX Czech Republic Grants National Authorisation for TLX591 Kit
16/02/21	PRICE SENSITIVE	211.79KB	Share
TLX Notification of Conference Call for FY2020 Results
16/02/21		192.08KB	Share
TLX Collaboration with Heidelberg University Hospital
10/02/21		202.43KB	Share
TLX Telix Pursues Direct Benelux Product Distribution
08/02/21		214.02KB	Share
TLX Appendix 3G - issue of unlisted share options
29/01/21		232.02KB	Share
TLX Appendix 4C and Activities Report for December 2020 Quarter
29/01/21	PRICE SENSITIVE	1.34MB	Share
TLX First US patients dosed in Ph III ZIRCON trial
25/01/21		226.92KB	Share
TLX TLX101 Glioblastoma Therapy - Clinical Update
23/12/20		213.92KB	Share
TLX Cleansing Notice under section 708A Corporations Act
17/12/20		74.55KB	Share
TLX Appendix 2A - issue of shares from exercise of options
17/12/20		226.81KB	Share
TLX Change in substantial holding
17/12/20		685.08KB	Share
TLX New Drug Submission filed with Health Canada for TLX591-CDx
16/12/20	PRICE SENSITIVE	218.89KB	Share
TLX Urologic Oncology Alliance with Mauna Kea Technologies
16/12/20		203.05KB	Share
TLX IP Agreement with U Southampton for access to TRALA data
14/12/20	PRICE SENSITIVE	219.58KB	Share
TLX Cleansing Notice under section 708A Corporations Act
14/12/20		74.66KB	Share
TLX Appendix 2A - issue of shares from exercise of options
14/12/20		225.52KB	Share
TLX Appendix 2A - shares issued as consideration for acquisition
14/12/20		236.33KB	Share
TLX Telix Completes Acquisition of TheraPharm GmbH
14/12/20	PRICE SENSITIVE	208.43KB	Share
TLX Telix and Kanazawa University Phase I trial of TLX591-CDx
14/12/20		211.07KB	Share
TLX Release of shares from voluntary escrow
10/12/20		190.32KB	Share
TLX FDA New Drug Application for TLX591-CDx Proceeds to Review
09/12/20	PRICE SENSITIVE	222.21KB	Share
TLX TGA Priority Review Granted for Prostate Cancer Imaging
07/12/20	PRICE SENSITIVE	211.48KB	Share
TLX Overview of ProstACT Phase III Study - Investor supplement
03/12/20		8.92MB	Share
TLX ProstACT Phase III Study Clinical Development Update
03/12/20	PRICE SENSITIVE	214.29KB	Share
TLX Telix and DuChemBio - South Korea Partnership
03/12/20	PRICE SENSITIVE	223.7KB	Share
TLX Investor Briefing on First-in-Human Translation of TLX592
02/12/20		2.12MB	Share
TLX Approval for Ph I study of next generation product TLX592
02/12/20		210.83KB	Share
TLX FDA Approves 68Ga-PSMA Imaging for Use at UCLA and UCSF
02/12/20		211.09KB	Share
TLX Briefing for Investor call - TheraPharm GmbH Acquisition
01/12/20	PRICE SENSITIVE	1.98MB	Share
TLX Acquisition of TheraPharm GmbH - Investor Call
30/11/20	PRICE SENSITIVE	190.7KB	Share
TLX Proposed issue of Securities - TLX
30/11/20		25.02KB	Share
TLX Telix Acquires TheraPharm GmbH
30/11/20	PRICE SENSITIVE	252.49KB	Share
TLX Trading Halt
27/11/20	PRICE SENSITIVE	278.66KB	Share
TLX Prostate Cancer Therapy FDA Meeting Update
25/11/20	PRICE SENSITIVE	205.99KB	Share
TLX NDA for Prostate Cancer Imaging accepted by US FDA
24/11/20	PRICE SENSITIVE	220.55KB	Share
TLX TLX receives EUR545k Belgian Research Grant
19/11/20		211.91KB	Share
TLX Becoming a substantial holder
09/11/20		5.97MB	Share
TLX App 2A quotation for shares issued in strategic transaction
06/11/20		234.14KB	Share
TLX Appendix 3Y - change in Director interests - O Buck
03/11/20		216.93KB	Share
TLX Cleansing Notice - issue of shares from exercise of options
03/11/20		74.75KB	Share
TLX Appendix 2A - issue of shares on exercise of options
03/11/20		225.14KB	Share
TLX Investor Briefing - Asia Strategy
03/11/20	PRICE SENSITIVE	2.42MB	Share
TLX Investor Call - Strategic Licence and Commercial Partnership
02/11/20		191.84KB	Share
TLX Appendix 3B - Proposed Issue of Securities
02/11/20		664.79KB	Share
TLX Strategic Licence and Partnership for Greater China Market
02/11/20	PRICE SENSITIVE	244.19KB	Share
TLX Trading Halt
30/10/20	PRICE SENSITIVE	278.57KB	Share
TLX App 4C and Activities Report for September 2020 Quarter
30/10/20	PRICE SENSITIVE	1.31MB	Share
TLX Licence Agmt with DKFZ for Image-Guided Prostate Surgery
28/10/20		220.09KB	Share
TLX Completion of PhI Enrolment of Japanese Renal Cancer Study
27/10/20		206.79KB	Share
TLX Appendix 3G - issue of Rights under Equity Incentive Plan
13/10/20		234.11KB	Share
TLX FDA grants Orphan Drug Designation for glioma imaging agent
06/10/20	PRICE SENSITIVE	216.44KB	Share
TLX Telix submits NDA to US FDA for Prostate Cancer Imaging
24/09/20	PRICE SENSITIVE	206.06KB	Share
TLX First patients dosed in Phase I study of APOMAB theranostic
21/09/20		205.38KB	Share
TLX Strategic Collaboration with Varian for Prostate Imaging
03/09/20	PRICE SENSITIVE	217.32KB	Share
TLX IRE Distribution Partnership for Prostate Cancer Imaging
01/09/20	PRICE SENSITIVE	206.15KB	Share
TLX FDA grants orphan drug designation for TLX102
31/08/20	PRICE SENSITIVE	203.85KB	Share
TLX Half Year Shareholder Update
21/08/20		3.09MB	Share
TLX Report for half-year to 30 June 2020
20/08/20	PRICE SENSITIVE	951.8KB	Share
TLX First patient dosed in renal cancer imaging study in Japan
18/08/20		210.46KB	Share
TLX Drug Master File for Glioblastoma Product Filed with FDA
11/08/20		209.75KB	Share
TLX Investor call - H1 Results and Company Update
11/08/20		198.31KB	Share
TLX Appendix 4C and Activities Report - June 2020 quarter
27/07/20	PRICE SENSITIVE	1.25MB	Share
TLX Receipt of $11.4M R&D tax rebate
21/07/20	PRICE SENSITIVE	204.14KB	Share
TLX App 2A - issue of shares following exercise of options
15/07/20		167.63KB	Share
TLX Strategic collaboration with RefleXion for high-risk cancers
08/07/20		187.55KB	Share
TLX FDA feedback on Prostate Cancer Therapy Phase 3 Trial Design
08/07/20		188.15KB	Share
TLX App 3G - issue and lapse of unlisted share options
02/07/20		353.15KB	Share
TLX FDA grants breakthrough designation for TLX250-CDx product
01/07/20	PRICE SENSITIVE	197.32KB	Share
TLX Recommencement of ZIRCON Phase III Trial Recruitment in EU
18/06/20		180.7KB	Share
TLX S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20	PRICE SENSITIVE	223.16KB	Share
TLX Update on New Drug Application for Prostate Cancer Imaging
10/06/20		179.58KB	Share
TLX Presentation to Jefferies Virtual Healthcare Conference
04/06/20		13.7MB	Share
TLX Appointment of Dr Colin Hayward as Chief Medical Officer
02/06/20		188.6KB	Share

REFRESH

First 4 5 6 7 8

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $17.64		Change -0.560(3.08%)		Mkt cap ! $5.969B

Open	High	Low	Value	Volume
$18.04	$18.04	$17.37	$63.83M	3.628M

Buyers (Bids)

No.	Vol.	Price($)
1	17	$17.64

Sellers (Offers)

Price($)	Vol.	No.
$17.66	100	1

View Market Depth

No.	Vol.	Price($)
1	17	17.640
1	1000	17.600
1	19	17.560
1	100	17.540
9	2069	17.500

Price($)	Vol.	No.
17.750	460	1
17.770	400	1
17.800	2030	2
17.830	509	1
17.850	559	2

Last trade - 16.18pm 08/08/2025 (20 minute delay)

TLX (ASX) Chart

TELIX PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories